StreetInsider.com News Articles

FDA lifts clinical hold on Arbutus Biopharma's AB-101 drug candidate

Thu, 22 Oct 2026 07:31:52 -0400

Arbutus Biopharma Corporation (NASDAQ: ABUS) announced that the U.S. Food and Drug Administration has lifted a clinical hold on the Investigational New Drug application for AB-101, an oral PD-L1 inhibitor being developed for chronic hepatitis B virus infection. The company said it is evaluating next steps for continued development of the drug.

AB-101 is designed to activate patients' hepatitis B virus-specific immune response by inhibiting PD-L1. The drug has completed a Phase 1a/1b clinical trial evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of single- and multiple-ascending oral doses in healthy subjects and patients with chronic HBV infection.

Data from the trial showed AB-101

FDA lifts clinical hold on Arbutus Biopharma's AB-101 drug candidate

Thu, 22 Oct 2026 07:31:52 -0400

Data from the trial showed AB-101

FDA lifts clinical hold on Arbutus Biopharma's AB-101 drug candidate

Thu, 22 Oct 2026 07:31:52 -0400

Data from the trial showed AB-101

Form 8-K Arbutus Biopharma Corp For: Oct 20

Thu, 22 Oct 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20261022/27219042.html

Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor

Thu, 22 Oct 2026 07:30:00 -0400

WARMINSTER, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that the Company was notified by the U.S. Food and Drug Administration (“FDA”) that the clinical hold on the Investigational New Drug (“IND”) application for AB-101 has been removed and that the Company may engage in additional clinical development for AB-101 in the United States. Arbutus is evaluating next steps for the continued development of AB-101.

AB-101 is a proprietary oral PD-L1 inhibitor that has the potential to

Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor

Thu, 22 Oct 2026 07:30:00 -0400

AB-101 is a proprietary oral PD-L1 inhibitor that has the potential to

Form SCHEDULE 13G/A Arbutus Biopharma Corp Filed by: MORGAN STANLEY

Wed, 07 Oct 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20261007/27161668.html

Form 4 Arbutus Biopharma Corp For: Oct 01 Filed by: Nguyen Tuan

Wed, 07 Oct 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20261007/27161355.html

Form 4 Arbutus Biopharma Corp For: Oct 01 Filed by: Beardsley Robert A

Wed, 07 Oct 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20261007/27161361.html

Form 4 Arbutus Biopharma Corp For: Oct 01 Filed by: Sawhney Roger

Wed, 07 Oct 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20261007/27161334.html

Form 4 Arbutus Biopharma Corp For: Oct 01 Filed by: Androski Lindsay

Wed, 07 Oct 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20261007/27161323.html

Increasing unusual option volume: ABUS PACB DNA GMAB TWST HHH

Wed, 07 Oct 2026 06:13:27 -0400

Increasing unusual option volume: ABUS PACB DNA GMAB TWST HHH

Form SCHEDULE 13D/A Arbutus Biopharma Corp Filed by: Roivant Sciences Ltd.

Mon, 05 Oct 2026 21:02:00 -0400

si-local-file:///var/storage/secattach/20261005/27150546.html

Form 4 Arbutus Biopharma Corp For: Oct 01 Filed by: Roivant Sciences Ltd.

Mon, 05 Oct 2026 21:00:00 -0400

si-local-file:///var/storage/secattach/20261005/27150545.html

Form SC TO-I/A Arbutus Biopharma Corp Filed by: Arbutus Biopharma Corp

Thu, 01 Oct 2026 07:36:00 -0400

si-local-file:///var/storage/secattach/20261001/27131624.html

Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer

Thu, 01 Oct 2026 07:30:00 -0400

WARMINSTER, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the final results of its tender offer (the “Offer”) to purchase for cancellation up to US$230 million in value of its common shares (the “Shares”). The Offer proceeded by way of a modified Dutch auction, which had a tender price range from US$5.00 per Share to US$5.75 per Share, and included the option for shareholders to participate via a proportionate tender. The Offer expired at 5:00 p.m. (New York City

Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer

Thu, 01 Oct 2026 07:30:00 -0400

Form SC TO-I/A Arbutus Biopharma Corp Filed by: Arbutus Biopharma Corp

Wed, 30 Sep 2026 07:36:00 -0400

si-local-file:///var/storage/secattach/20260930/27125355.html

Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer

Wed, 30 Sep 2026 07:30:00 -0400

WARMINSTER, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the preliminary results of its tender offer (the “Offer”) to purchase for cancellation up to US$230 million in value of its common shares (the “Shares”). The Offer proceeded by way of a modified Dutch auction, which had a tender price range from US$5.00 per Share to US$5.75 per Share, and included the option for shareholders to participate via a proportionate tender. The Offer expired at 5:00 p.m. (New York City

Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer

Wed, 30 Sep 2026 07:30:00 -0400

Increasing unusual option volume: ABUS KOD FHN GRAL ACAD XIFR GXO ADMA PACS

Tue, 29 Sep 2026 05:46:27 -0400

Increasing unusual option volume: ABUS KOD FHN GRAL ACAD XIFR GXO ADMA PACS

Increasing unusual call option volume: ERAS ABUS SGHC AKAM XLU KOD ACMR BBD

Mon, 28 Sep 2026 05:49:13 -0400

Increasing unusual call option volume: ERAS ABUS SGHC AKAM XLU KOD ACMR BBD

Increasing unusual option volume: ABUS GFL OI GETY RNG FEZ ERIC

Thu, 24 Sep 2026 06:14:08 -0400

Increasing unusual option volume: ABUS GFL OI GETY RNG FEZ ERIC

Form 4 Arbutus Biopharma Corp For: Sep 18 Filed by: Nguyen Tuan

Wed, 23 Sep 2026 20:32:00 -0400

si-local-file:///var/storage/secattach/20260923/27097724.html

Form 4 Arbutus Biopharma Corp For: Sep 18 Filed by: Androski Lindsay

Wed, 23 Sep 2026 20:32:00 -0400

si-local-file:///var/storage/secattach/20260923/27097725.html